Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 4Completed 3Active not recruiting 2Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 19Gastrointestinal 5Thoracic 4CNS 3Tumor-Agnostic 2Sarcoma 1Head & Neck 1Gynecologic 1

Conditions

Neoplasm Metastasis 2

Interventions

pembrolizumab 17Specimen Handling 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Paclitaxel 7Biopsy 7Nivolumab 6atezolizumab 5Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Practice Guidelines as Topic 4Pemetrexed 4Oxaliplatin 4Cyclophosphamide 4Carboplatin 4osimertinib 3niraparib 3durvalumab 3cemiplimab 3avelumab 3Radiotherapy 3Radiation 3Leucovorin 3Irinotecan 3Ipilimumab 3Interviews as Topic 3Fluorouracil 3trastuzumab deruxtecan 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × trastuzumab deruxtecan × Tumor-Agnostic × Clear all
NCT04639219 2026-03-23

DPT01

AstraZeneca

Phase 2 Active not recruiting
102 enrolled 18 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04294628 2026-02-27

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡